__NUXT_JSONP__("/drugs/Orelabrutinib", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1655504-04-3",chebiId:b,chemicalFormula:b,definition:"A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK\u002FTec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.",fdaUniiCode:"WJA5UO9E10",identifier:"C156173",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C124801","C129825"],synonyms:["BTK Inhibitor ICP-022","ICP 022","ICP-022","ICP022","ORELABRUTINIB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FOrelabrutinib",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Orelabrutinib","","2021-10-30T13:34:19.463Z")));